Driven to Failure: An Empirical Analysis of Driver’s License Suspension in North Carolina

A person’s interest in a driver’s license is “substantial,” and as the U.S. Supreme Court has observed, the suspension of a license by the state can result in “inconvenience and economic hardship suffered,” including because a license may be “essential in the pursuit of a livelihood.” However, forty-four U.S. states currently require indefinite suspension of driver’s licenses for non-driving-related reasons, such as failure to appear in court or pay fines for traffic infractions. There are no systematic, peer-reviewed analyses of individual-level or county-level data regarding such suspensions. This study describes North Carolina’s population of suspended drivers and assesses how driver’s license suspension statutes operate relative to geography, race, and poverty level. First, it analyzes four decades of active-suspension data in North Carolina and finds over 1,225,000 active suspensions for failures to appear or pay traffic fines, amounting to one in seven adult drivers in the state. Second, it compares these data to county-population data; county-level traffic-stop data, collected as required by statute in North Carolina; and county-level data on the volume and composition of traffic court dockets. This study reveals that driver’s license suspensions are not associated with either the volume of traffic stops or the size of the traffic court docket. In contrast, we find that black and Latinx people are overrepresented relative to the population. Linear mixed-level modeling regression analyses demonstrate that the population of white people below the poverty line and black people above the poverty line are most strongly associated with more suspensions. Finally, this Article explores implications of these results for efforts to reconsider the imposition of driver’s license suspensions for non-driving-related reasons. These patterns raise constitutional concerns and practical challenges for policy efforts to undo such large-scale suspension of driving privileges

Automatically Guilty: Associations Between Evidence and Guilt

Both real-life cases and laboratory research demonstrate that confession evidence is very convincing—even when it should not be. Could this be due to an automatic association between a confession and guilt? We tested this possibility using a Deese-Roediger-McDermott (DRM) list, which measures automatic associations by presenting participants with a list of words that are thematically related but, importantly, lack the word describing the theme (“critical lure”). When the association between the list words and the theme is sufficiently strong, participants incorrectly report seeing the critical lure. We hypothesized that participants would show more false recall for seeing “guilty” on a “guilty”-themed DRM list when the list included evidence that is automatically associated with guilt, such as “confession” and “DNA.” Although our previous research on this topic found no significant effects, we addressed limitations of that research in three studies using an Amazon MechanicalTurk sample. Our first study addressed a possible ceiling effect by decreasing the associative strength of our “guilty” list. Our second study increased external validity by presenting our DRM List as a DRM Story—a narrative format that provides context for the list words. Our third study investigated the effects of priming evidence quality on the association to guilty. Overall, we found little support for our hypotheses. Across all three studies, we did not detect any effects of the evidence type (Study 1, 2, and 3) or prime type (Study 3). We did, however, find several interesting trends in the data. We discuss explanations for the lack of significant findings and address directions for future research. Specifically, adapting this paradigm for other research applications and to increase our understanding of the memorial effects of the “guilty” DRM list

Rethinking the Ken Through the Lens of Psychological Science

Canadian courts regularly exclude psychological expert evidence that would explain the factors that produce mistaken eyewitness identifications and false confessions (two significant sources of wrongful convictions). Courts justify these exclusions on the basis that the evidence is not beyond the ken of the trier of fact—the psychologist would simply be describing an experience shared by the judge and jury. In this article, the authors suggest this reasoning rests on two fundamental misunderstandings of psychology: unconscious neglect and dispositionism. In other words, judges mistakenly assume the trier of fact understands the unconscious situational forces that distort memories and cause innocent people to confess. Moreover, judges appear to prefer dispositional evidence of some disorder or syndrome suffered by the accused or by the witness to the crime. After demonstrating evidence of such reasoning in several decisions, the authors suggest reforms based on a more nuanced understanding of human psychology

Mock Jurors’ Evaluation of Firearm Examiner Testimony

Objectives: Firearms experts traditionally have testified that a weapon leaves “unique” toolmarks, so bullets or cartridge casings can be visually examined and conclusively matched to a particular firearm. Recently, due to scientific critiques, Department of Justice policy, and judges’ rulings, firearms experts have tempered their conclusions. In two experiments, we tested whether this ostensibly more cautious language has its intended effect on jurors (Experiment 1), and whether cross-examination impacts jurors’ perception of firearm testimony (Experiment 2). Hypotheses: Four hypotheses were tested. First, jurors will accord significant weight to firearm testimony that declares a “match” compared to testimony that does not (Experiments 1 and 2). Second, variations to “match” language will not affect guilty verdicts (Experiment 1). Third, only the most cautious language (“cannot exclude the gun”) would lower guilty verdicts (Experiment 1). Fourth, cross-examination will reduce guilty verdicts depending on specific language used (Experiment 2). Method: In two preregistered, high-powered experiments with 200 mock jurors per cell, participants recruited from Qualtrics Panels were presented with a criminal case containing firearms evidence, which varied the wording of the examiner’s conclusion and whether cross-examination was present. These variations include conclusion language used by practitioners, language advised by government organizations, and language required by judges in several cases. Participants gave a verdict, rated the evidence and expert in all conditions. Results: Guilty verdicts significantly increased when a match was declared compared to when a match was not declared. Variation in conclusion language did not affect guilty verdicts nor did it affect jurors’ estimates of the likelihood the defendant’s gun fired the bullet recovered at the crime scene. In contrast, however, a more cautious conclusion that an examiner “cannot exclude the defendant’s gun” did significantly reduce guilty verdicts and likelihood estimates alike. The presence of cross-examination did not affect these findings. Conclusion: Apart from the most limited language (“cannot exclude the defendant’s gun”), judicial intervention to limit firearms conclusion language is not likely to produce its intended effect. Moreover, cross-examination does not appear to affect perceptions or individual juror verdicts

Evaluation Research and Institutional Pressures: Challenges in Public-Nonprofit Contracting

This article examines the connection between program evaluation research and decision-making by public managers. Drawing on neo-institutional theory, a framework is presented for diagnosing the pressures and conditions that lead alternatively toward or away the rational use of evaluation research. Three cases of public-nonprofit contracting for the delivery of major programs are presented to clarify the way coercive, mimetic, and normative pressures interfere with a sound connection being made between research and implementation. The article concludes by considering how public managers can respond to the isomorphic pressures in their environment that make it hard to act on data relating to program performance.This publication is Hauser Center Working Paper No. 23. The Hauser Center Working Paper Series was launched during the summer of 2000. The Series enables the Hauser Center to share with a broad audience important works-in-progress written by Hauser Center scholars and researchers

Being Ready to Treat Ebola Virus Disease Patients

As the outbreak of Ebola virus disease (EVD) in West Africa continues, clinical preparedness is needed in countries at risk for EVD (e.g., United States) and more fully equipped and supported clinical teams in those countries with epidemic spread of EVD in Africa. Clinical staff must approach the patient with a very deliberate focus on providing effective care while assuring personal safety. To do this, both individual health care providers and health systems must improve EVD care. Although formal guidance toward these goals exists from the World Health Organization, Medecin Sans Frontières, the Centers for Disease Control and Prevention, and other groups, some of the most critical lessons come from personal experience. In this narrative, clinicians deployed by the World Health Organization into a wide range of clinical settings in West Africa distill key, practical considerations for working safely and effectively with patients with EVD

Animal models for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (frst detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the fndings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.info:eu-repo/semantics/acceptedVersio

Evidence-based guidelines for supportive care of patients with Ebola virus disease.

The 2013-16 Ebola virus disease outbreak in west Africa was associated with unprecedented challenges in the provision of care to patients with Ebola virus disease, including absence of pre-existing isolation and treatment facilities, patients' reluctance to present for medical care, and limitations in the provision of supportive medical care. Case fatality rates in west Africa were initially greater than 70%, but decreased with improvements in supportive care. To inform optimal care in a future outbreak of Ebola virus disease, we employed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to develop evidence-based guidelines for the delivery of supportive care to patients admitted to Ebola treatment units. Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief

2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales.

Correction to: 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology (2021) 166:3567–3579. https://doi.org/10.1007/s00705-021-05266-wIn March 2021, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by four families (Aliusviridae, Crepuscuviridae, Myriaviridae, and Natareviridae), three subfamilies (Alpharhabdovirinae, Betarhabdovirinae, and Gammarhabdovirinae), 42 genera, and 200 species. Thirty-nine species were renamed and/or moved and seven species were abolished. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.This work was supported in part through Laulima Government Solutions, LLC prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272201800013C. J.H.K. performed this work as an employee of Tunnell Government Services (TGS), a subcontractor of Laulima Government Solutions, LLC under Contract No. HHSN272201800013C. This work was also supported in part with federal funds from the National Cancer Institute (NCI), National Institutes of Health (NIH), under Contract No. 75N91019D00024, Task Order No. 75N91019F00130 to I.C., who was supported by the Clinical Monitoring Research Program Directorate, Frederick National Lab for Cancer Research. This work was also funded in part by Contract No. HSHQDC-15-C-00064 awarded by DHS S&T for the management and operation of The National Biodefense Analysis and Countermeasures Center, a federally funded research and development center operated by the Battelle National Biodefense Institute (V.W.); and NIH contract HHSN272201000040I/HHSN27200004/D04 and grant R24AI120942 (N.V., R.B.T.). S.S. acknowledges partial support from the Special Research Initiative of Mississippi Agricultural and Forestry Experiment Station (MAFES), Mississippi State University, and the National Institute of Food and Agriculture, US Department of Agriculture, Hatch Project 1021494. Part of this work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001030), the UK Medical Research Council (FC001030), and the Wellcome Trust (FC001030).S

Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function

Background: Cardiovascular disease is a major comorbidity of rheumatoid arthritis (RA) and a leading cause of death. Chronic systemic inflammation involving tumour necrosis factor alpha (TNF) could contribute to endothelial activation and atherogenesis. A number of anti-TNF therapies are in current use for the treatment of RA, including certolizumab pegol (CZP), (Cimzia ®; UCB, Belgium). Anti-TNF therapy has been associated with reduced clinical cardiovascular disease risk and ameliorated vascular function in RA patients. However, the specific effects of TNF inhibitors on endothelial cell function are largely unknown. Our aim was to investigate the mechanisms underpinning CZP effects on TNF-activated human endothelial cells. Methods: Human aortic endothelial cells (HAoECs) were cultured in vitro and exposed to a) TNF alone, b) TNF plus CZP, or c) neither agent. Microarray analysis was used to examine the transcriptional profile of cells treated for 6 hrs and quantitative polymerase chain reaction (qPCR) analysed gene expression at 1, 3, 6 and 24 hrs. NF-κB localization and IκB degradation were investigated using immunocytochemistry, high content analysis and western blotting. Flow cytometry was conducted to detect microparticle release from HAoECs. Results: Transcriptional profiling revealed that while TNF alone had strong effects on endothelial gene expression, TNF and CZP in combination produced a global gene expression pattern similar to untreated control. The two most highly up-regulated genes in response to TNF treatment were adhesion molecules E-selectin and VCAM-1 (q 0.2 compared to control; p > 0.05 compared to TNF alone). The NF-κB pathway was confirmed as a downstream target of TNF-induced HAoEC activation, via nuclear translocation of NF-κB and degradation of IκB, effects which were abolished by treatment with CZP. In addition, flow cytometry detected an increased production of endothelial microparticles in TNF-activated HAoECs, which was prevented by treatment with CZP. Conclusions: We have found at a cellular level that a clinically available TNF inhibitor, CZP reduces the expression of adhesion molecule expression, and prevents TNF-induced activation of the NF-κB pathway. Furthermore, CZP prevents the production of microparticles by activated endothelial cells. This could be central to the prevention of inflammatory environments underlying these conditions and measurement of microparticles has potential as a novel prognostic marker for future cardiovascular events in this patient group. Disclosure statement: Y.A. received a research grant from UCB. I.B. received a research grant from UCB. S.H. received a research grant from UCB. All other authors have declared no conflicts of interes